pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
sniff results

“PDUFA”

12 total hits · 0 drugs · 0 companies · 0 diseases · 7 catalysts · 5 news

Drugs(0)

expand →
no drug names matched

🐶 Companies(0)

expand →
no companies matched

Catalysts(7)

expand →
Jan 21, 2027
pdufa
in 5mo
PDUFA — 2027-01-21
Ultragenyx Pharmaceutical Inc.
→
Jan 4, 2027
pdufa
in 4mo
PDUFA — 2027-01-04
→
Jul 17, 2026
pdufa
2mo ago
PDUFA — 2026-07-17
→
Apr 30, 2026
pdufa
4mo ago
Axsome Therapeutics Inc — (bupropion hydrochloride + dextromethorphan) ER (PDUFA)
(bupropion hydrochloride + dextromethorphan) ER
→
Apr 29, 2026
pdufa
4mo ago
Sanofi — teplizumab (PDUFA)
teplizumab
→
Apr 28, 2026
pdufa
4mo ago
Merck & Co Inc — (doravirine + islatravir hydrate) (PDUFA)
(doravirine + islatravir hydrate)
→
Apr 27, 2026
pdufa
4mo ago
Regeneron Pharmaceuticals Inc — dupilumab (PDUFA)
dupilumab
→

News(5)

expand →
  • FDA delays Capricor's deramiocel PDUFA date to review new data↗
    The FDA is pushing back its decision on Capricor Therapeutics’ problematic Duchenne muscular dystrophy therapy to review additional data for a more niche indication. The company on Monday said the…
    endpoints · 13d ago
  • Capricor investor calls for change as company awaits decision on Duchenne candidate↗
    Kaos Capital in a letter to other Capricor Therapeutics shareholders called for “an immediate meeting, board change, and capital-preservation plan.” The biotech recently put all other pipeline work…
    biospace · 16d ago
  • PDUFA VIII commitments: 'America First' provisions, faster reviews and more↗
    The FDA's next five-year reauthorization of the prescription drug user fee program will feature new incentives for domestic pharma companies, newly sped up reviews for some applications, and improv…
    endpoints · 24d ago
  • PDUFA VIII: FDA outlines goals, program enhancements in commitment letter
↗
The US Food and Drug Administration (FDA) on Thursday released its proposed commitment letter for the Prescription Drug User Fee Act (PDUFA VIII) program, outlining its performance goals and progra…
raps · 24d ago
  • AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave↗
    Plus news about Kailera, Alfasigma, Junshi and Kura. ⏰ FDA delays AstraZeneca’s camizestrant PDUFA date: The FDA has extended its PDUFA date for AstraZeneca’s breast cancer drug camizestrant, a few…
    endpoints · 3mo ago
  • $REGN827.72-1.87%
    $RARE15.30+3.03%
    $MRK150.33-1.32%
    $AXSM206.68-0.80%
    $SNY44.24-0.20%